Last reviewed: May 29, 2026
Last updated: May 29, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
NAD+ injection dosing ranges from 250 mg to 1000 mg per week depending on baseline NAD+ levels, age, and metabolic status. Most clinicians start conservatively and titrate based on response and tolerability, not on a one-size-fits-all standard.
Determining your appropriate NAD+ dose requires understanding your current NAD+ biomarkers and how your body metabolizes cellular therapies. PlexusDx advocates for precision wellness through biomarker-guided dosing—a principle that applies equally to peptide and NAD+ protocols.
NAD+ Dosing: Starting Dose and Titration Frameworks
Most providers initiate NAD+ therapy at 250–500 mg per week as an intramuscular or intravenous injection. This conservative start allows assessment of tolerance, energy response, and any adverse reactions before upward adjustment.
Titration typically follows a 2–4 week observation window. If baseline energy, cognitive clarity, and recovery metrics improve without adverse effects, doses may increase by 250 mg increments up to 750–1000 mg weekly. Individual response varies widely based on age, mitochondrial fitness, and prior NAD+ depletion.
Biomarker Assessment: Why Baseline NAD+ Levels Matter
Before starting NAD+ therapy, a baseline serum or urinary NAD+ metabolite panel can reveal your current NAD+ status and inform initial dosing strategy. Lower baseline levels often predict greater clinical benefit from supplementation and may warrant faster titration protocols.
Biomarkers such as NAD+ metabolites (nicotinamide mononucleotide, nicotinamide riboside), mitochondrial function markers (citrate synthase activity), and metabolic health indicators (fasting glucose, VO2 max) all contribute to personalized dosing decisions.
| Biomarker |
Low Range |
Optimal Range |
Dosing Implication |
| Serum NAD+ Level |
<400 µM |
400–700 µM |
May benefit from higher starting dose or faster titration |
| NAD+/NADH Ratio |
<1.5 |
>2.0 |
Low ratio suggests mitochondrial stress; consider conservative start |
| Lactate at Rest |
>2 mmol/L |
<1.5 mmol/L |
Elevated lactate may indicate NAD+ deficiency; monitor during dosing |
| Mitochondrial Function Score |
<40% |
>70% |
Lower scores warrant biomarker re-check at 4–6 weeks post-initiation |
Age and Metabolic Status: Key Variables in Dose Selection
Chronological age and metabolic age influence NAD+ responsiveness. Adults over 50 with declining NAD+ levels may require higher doses (750–1000 mg weekly) compared to younger individuals, who often respond to 250–500 mg doses.
Concurrent metabolic conditions—insulin resistance, chronic inflammation, sedentary lifestyle—also affect optimal dosing. Individuals with metabolic dysfunction may benefit from lower initial doses paired with lifestyle modification, then gradual titration as metabolic capacity improves.
Provider Oversight, Monitoring, and Safety Considerations
NAD+ injection therapy should always occur under qualified healthcare provider supervision. A provider will establish baseline bloodwork, assess for contraindications, and establish a monitoring schedule to evaluate efficacy and safety at 2–4 week intervals.
Regular monitoring includes symptom tracking (energy, sleep quality, cognitive function), repeat NAD+ biomarkers at 6–12 weeks, and liver and kidney function tests. Adverse effects—headache, flushing, nausea—typically resolve with dose reduction or slower titration. Do not self-adjust without provider guidance.
How PlexusDx Supports a More Personalized Approach
PlexusDx applies the same biomarker-informed precision philosophy to compounded GLP-1 peptides as detailed here for NAD+ dosing. Understanding your baseline metabolic state and genetic predispositions—revealed through tools like the Precision Peptide Genetic Test—may help provide context for how your body metabolizes injectable therapies.
The Precision Peptide Genetic Test examines variants in GIPR, GLP1R, FTO, and MC4R pathways, which reflect broader metabolic and appetite-regulation genetics. While this test is designed for GLP-1 response patterns, it underscores the principle that genetic and biomarker context shapes individual dose requirements and therapeutic efficacy across peptide and cellular therapies.
Whether pursuing NAD+ therapy or compounded peptide protocols like semaglutide or tirzepatide, working with a qualified provider who integrates biomarker data and genetic predispositions supports more informed, personalized dosing conversations. A comprehensive approach—baseline labs, genetic insights, and regular monitoring—reduces guesswork and enhances safety.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $179-$229/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is there a standard NAD+ injection dose everyone should use?
No. NAD+ dosing varies widely based on baseline NAD+ levels, age, metabolic health, and individual response. Starting doses typically range 250–500 mg weekly, with adjustments guided by provider monitoring and biomarker tracking.
How quickly should NAD+ dose be increased?
Conservative titration is standard: start at 250–500 mg weekly, assess tolerance and response over 2–4 weeks, then increase by 250 mg increments if tolerated. Rapid increases raise adverse-effect risk and are not recommended without provider oversight.
What biomarkers should I check before starting NAD+ therapy?
Baseline serum NAD+ level, NAD+/NADH ratio, mitochondrial function markers, fasting glucose, and liver/kidney function are valuable. These inform initial dosing strategy and provide a baseline for monitoring efficacy at 6–12 weeks.
Can NAD+ injection cause side effects at higher doses?
Yes. Common dose-related side effects include headache, flushing, nausea, and fatigue. These typically resolve with dose reduction or slower titration. Serious adverse effects are rare but require provider evaluation. Never self-adjust without medical guidance.
How does NAD+ dosing relate to genetic or peptide therapies?
Both NAD+ and peptide therapies benefit from biomarker-guided, personalized dosing rather than generic protocols. PlexusDx's Precision Peptide Genetic Test reveals predispositions in metabolic pathways relevant to peptide response—a principle that extends to all cellular therapies, including NAD+ protocols.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Sermorelin Reviews: Clinical Evidence and Personalized Expectations
How To Get Sermorelin: Clinical Eligibility and Provider-Guided Access